Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)

Launched by CHINESE PLA GENERAL HOSPITAL · Jul 20, 2025

Keywords

ClinConnect Summary

This clinical trial, called AD-MINER, is studying Alzheimer’s disease by using advanced brain imaging techniques to better understand how the disease develops over time. The researchers will enroll 750 people, including those with normal memory, mild memory problems, and Alzheimer’s disease. Participants will have detailed brain scans using special MRI machines, blood tests, and memory and thinking tests at the start of the study and then once a year. The goal is to find early signs in the brain that show how Alzheimer’s progresses, which could help with earlier diagnosis and better treatments in the future.

To join the study, you need to be between 55 and 90 years old and able to have MRI scans safely. People will be grouped based on their memory and thinking abilities: those with normal cognition, mild memory concerns but no dementia, and those diagnosed with Alzheimer’s disease. Participants should be willing to take part in all follow-up visits and provide blood samples. The study excludes people with other serious brain diseases, major psychiatric conditions, or health issues that would make it hard to complete the study. If you join, you can expect to have regular brain scans, blood tests, and memory assessments over several years to help researchers learn more about Alzheimer’s disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 55-90 years (inclusive).
• • Willing and able to participate in baseline assessment and longitudinal follow-up; voluntary provision of biospecimens and personal information, and commitment to complete all follow-up visits.
• • Able to undergo MRI scanning (no contraindications to MRI).
• * Group-specific cognitive criteria:
• • CN: No subjective memory complaints beyond age expectation (confirmed by study partner); MMSE score 26-30 (inclusive; exceptions permitted for participants with \<8 years of education with principal investigator approval; CDR = 0, memory box = 0; Normal cognitive and daily functioning, no significant impairment.
• • MCI: Subject, partner, or physician reports subjective memory concerns; MMSE criteria same as CN group; CDR = 0.5 (memory box ≥0.5); General cognition and function relatively preserved; does not meet criteria for AD.
• • AD: Subject, partner, or physician reports subjective memory concerns; MMSE score \<26 (inclusive; exceptions as above); CDR = 0.5 or 1.0; Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) probable AD diagnostic criteria or 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (e.g., positive Pittsburgh compound B (PIB) and tau).
• Exclusion Criteria:
• • Self-reported or MRI-detected major neurological diseases other than AD: including but not limited to stroke (cerebral hemorrhage, infarction), congenital intellectual disability, intracranial tumors, epilepsy, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, severe head trauma with persistent deficits, etc.
• • Severe psychiatric disorders (e.g., schizophrenia requiring medication control) or other known brain structural abnormalities.
• • Significant organ failure (heart, liver, kidney, etc.), malignant tumors, or short life expectancy making completion of follow-up unlikely.
• • Contraindications to MRI (e.g., claustrophobia, incompatible pacemaker, aneurysm clip, artificial heart valve, cochlear implant, or other metallic implants).
• • Other clinical history or examination findings judged by investigators as potentially unsafe for MRI or follow-up.
• • Use of investigational drugs within one month prior to enrollment or during the study.